

RITUXIMAB PRESCRIBER ORDER FORM					
Patient Name: _____			Date of Birth: _____		Gender: _____
Address: _____					
Phone: _____		Height: _____		<input type="checkbox"/> inches <input type="checkbox"/> cm	Weight: _____
Clinical Information					
Primary Diagnosis Description: _____				ICD-10 Code: _____	
Is this the first dose?		Hepatitis B Status:		Titer Date:	
<input type="checkbox"/> Yes – date of first dose: _____		<input type="checkbox"/> No – date of last dose: _____		<input type="checkbox"/> Positive <input type="checkbox"/> Negative	
Rituximab Prescription					
<input type="checkbox"/> Rituximab biosimilar (e.g., Ruxience™, Riabni, or Truxima®) as permitted by patient's insurance <input type="checkbox"/> Rituximab (Rituxan®)					
<input type="checkbox"/> Infuse 375 mg/m ² IV once weekly for _____ doses. <input type="checkbox"/> Infuse 375 mg/m ² IV on Day 1 of each chemotherapy cycle for up to _____ infusions. <input type="checkbox"/> Infuse 1000 mg IV on Week 0 and Week 2. <input type="checkbox"/> Other: _____ Dose will be rounded to closest 100 mg vial.					
Ancillary Orders					
Anaphylaxis Kit Dosage: <ul style="list-style-type: none"> ▪ Epinephrine 0.3 mg (> 30 kg), 0.15 mg (15 to 30 kg), or 0.01 mg/kg (< 15 kg) SUBQ or IM x 1; repeat x 1 in 5 to 15 min PRN. ▪ Diphenhydramine 25 mg (> 30 kg) or 1.25 mg/kg (≤ 30 kg – max 25mg) IV or IM; repeat x 1 in 15 min PRN no improvement. ▪ 0.9% Sodium Chloride 500 mL (> 30 kg) or 250 mL (≤ 30 kg) IV at KVO rate PRN anaphylaxis. 					
Medication Orders <input type="checkbox"/> Acetaminophen _____ mg PO 30 min before infusion, may repeat every 3 to 4 hours as needed for fever or mild discomfort. Patient may decline. <input type="checkbox"/> Diphenhydramine _____ mg PO 30 min before infusion, may repeat every 4 to 6 hours as needed for mild to moderate allergic reactions. Patient may decline. <input type="checkbox"/> Methylprednisolone Sodium Succinate 100 mg IV push over at least 5 min; 30 min prior to infusion. <input type="checkbox"/> Other: _____					
IV Flush Orders <input type="checkbox"/> <u>Peripheral:</u> 0.9% Sodium Chloride 2 to 3 mL pre-/post-use. <input type="checkbox"/> <u>Implanted Port:</u> 0.9% Sodium Chloride 5 to 10 mL pre-/post-use and 10 to 20 mL pre-/post-lab draw. Heparin (100 unit/mL) 3 to 5 mL post-use. For maintenance, heparin (100 unit/mL) 3 to 5 mL every 24 hr if accessed or weekly to monthly if not accessed.					
Lab Orders <input type="checkbox"/> No labs ordered at this time. <input type="checkbox"/> Other: _____					
Skilled nurse to assess and administer and/or teach self-administration where appropriate via access device as indicated above. Nurse will provide ongoing support as needed. Refill above ancillary orders as directed x 1 year. If patient is seen within a provider led infusion clinic, Option Care Health's infusion reaction management policy, skilled nursing plan of treatment, and IV flush administration will be followed per provider oversight. No individual anaphylaxis kit will be dispensed.					
<i>I certify that the use of the indicated treatment is medically necessary, and I will be supervising the patient's treatment.</i>					
Prescriber Signature: _____				Date: _____	
Prescriber Information					
Prescriber Name: _____			Phone: _____		Fax: _____
Address: _____			NPI: _____		
City, State: _____		Zip: _____		Office Contact: _____	
Fax completed form, insurance information, and clinical documentation to: 713-983-4647					
CONFIDENTIAL HEALTH INFORMATION: Healthcare information is personal information related to a person's healthcare. It is being faxed to you after appropriate authorization or under circumstances that do not require authorization. You are obligated to maintain it in a safe, secure, and confidential manner. Re-disclosure of this information is prohibited unless permitted by law or appropriate customer/patient authorization is obtained. Unauthorized re-disclosure or failure to maintain confidentiality could subject you to penalties described in federal and state laws. IMPORTANT WARNING: This message is intended for the use of the person or entity to whom it is addressed and may contain information that is privileged and confidential, the disclosure of which is governed by applicable law. If the reader of this message is not the intended recipient, or the employee or agent responsible for delivering it to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this information is STRICTLY PROHIBITED. If you have received this message in error, please notify us immediately. Brand names are the property of their respective owners.					